ONC vs. SBTX, COS, C4XD, DDDD, OBI, POLB, SAR, OKYO, AREC, and AOR
Should you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Ondine Biomedical (OBI), Poolbeg Pharma (POLB), Sareum (SAR), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.
Oncimmune vs.
SkinBioTherapeutics (LON:SBTX) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
SkinBioTherapeutics has higher earnings, but lower revenue than Oncimmune. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
Oncimmune has a net margin of 586.08% compared to SkinBioTherapeutics' net margin of 0.00%. SkinBioTherapeutics' return on equity of -118.63% beat Oncimmune's return on equity.
In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Oncimmune'saverage media sentiment score.
Oncimmune received 21 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 25.0% of Oncimmune shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 31.0% of Oncimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
SkinBioTherapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Summary
Oncimmune beats SkinBioTherapeutics on 7 of the 13 factors compared between the two stocks.
Get Oncimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncimmune Competitors List
Related Companies and Tools
This page (LON:ONC) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ONC Stock Alerts